PLAAT3

Across TCGA pan-cancer cohorts, PLAAT3 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of PLAAT3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PLAAT3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PLAAT3 is over-expressed in tumor, although a few such as LUSC and BRCA show the opposite, repressed pattern.

KIRC, COAD, and THCA are the cancer types where PLAAT3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLAAT3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	+1.511	<.001	12	view →
COAD	All	III,IV	+1.551	<.001	11	view →
THCA	Male	All	+0.795	<.001	11	view →
LUSC	Female	All	−2.343	<.001	8	view →
BRCA	All	All	−1.158	<.001	8	view →
STAD	All	II,III,IV	+1.252	<.001	7	view →
UCEC	All	All	−1.475	<.001	6	view →
LUAD	All	All	−0.664	<.001	5	view →
LIHC	All	All	−0.620	.002	3	view →
KIRP	All	All	+0.837	.006	2	view →
HNSC	All	All	−0.648	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

PLAAT3–KIRC

Open the KIRC breakdown →